As one of the earliest specialized lymphoma diagnosis and treatment centers in China, the Department of Lymphoma Oncology has been anchored to the core goal of "safeguarding patients' life and health" since its establishment, consistently adhering to the service philosophy of "patient-centered care." Pioneering within the industry, it broke the limitations of traditional comprehensive diagnosis and treatment, promoting a specialized lymphoma diagnosis and treatment model. After years of dedicated development, it has become a nationally renowned specialized lymphoma diagnosis and treatment center, as well as a center for lymphoma hematopoietic stem cell transplantation and cellular immunotherapy. The Department of Lymphoma currently has 9 chief physicians, 2 deputy chief physicians, and 7 full-time scientific researchers, making it the professional team with the largest number of expert-level members in the global lymphoma field. Over the years, the department has focused on specialized development, implementing and promoting a multidisciplinary diagnosis and treatment model and standardized diagnosis and treatment pathways for lymphoma, which have become industry benchmarks in China. By integrating multidisciplinary expert resources, it customizes personalized and precise diagnosis and treatment plans for patients, enhancing both treatment efficacy and the patient experience. The proportion of lymphoma patients admitted has consistently ranked first in Beijing. In the field of scientific research and translation, the department boasts strong capabilities and fruitful achievements. It has established the earliest standardized clinical research platform in China, which is internationally leading, assembled a specialized full-time clinical research team, and developed a comprehensive management system. It continues to delve into basic and clinical translational research: as of 2024, it has received a total of 112 national, provincial, and ministerial-level scientific research project grants. As the first or corresponding author unit, it has published nearly 400 SCI papers in top-tier lymphoma journals such as *Lancet Oncology*, *Annals of Oncology*, *Lancet Haematology*, *Blood*, and *Journal of Hematology & Oncology*. Many research findings have provided key theoretical support for elucidating the pathogenesis of lymphoma and optimizing diagnosis and treatment protocols, leading to revisions of dozens of international and domestic guidelines. It has been awarded the Second Prize of the Chinese Medical Science and Technology Award. Addressing the treatment challenges for patients with refractory lymphoma, the department actively conducts innovative drug research. It has led or participated in over 300 domestic and international clinical registration studies, accounting for more than 75% of China's lymphoma new drug research and development, with over 80% of these projects being lead initiatives. This has provided nearly 3,000 patients with refractory lymphoma opportunities to participate in innovative drug clinical studies, opening a "new window" of life for these patients. Leveraging its strong clinical research capabilities, as of 2024, the department has successfully facilitated the approval and market launch of 31 new anti-lymphoma drugs or new indications in China, enabling cutting-edge domestic and international treatment protocols to be rapidly implemented in clinical practice, benefiting more patients. Notably, the department promoted the first domestically developed innovative anti-lymphoma drug to gain U.S. market approval based on clinical research data from the Chinese population, achieving a "zero breakthrough" in the overseas expansion of Chinese lymphoma new drugs and providing more high-quality and accessible treatment options for lymphoma patients worldwide. At the same time, the department actively plays a leading role in the industry, spearheading the development of 29 lymphoma specialty consensus statements and diagnosis and treatment guidelines covering the entire process of diagnosis, treatment, and follow-up for all lymphoma subtypes, establishing them as the "industry standard" for lymphoma diagnosis and treatment in China. Multiple research findings have received the highest level of recommendation in guidelines from the Chinese Society of Clinical Oncology (CSCO), the National Comprehensive Cancer Network (NCCN), and the European Society for Medical Oncology (ESMO), successfully incorporating China's lymphoma diagnosis and treatment experience into global guidelines. Through professional expertise, it is reshaping the global lymphoma treatment landscape and safeguarding patients' life and health.